{"organizations": [], "uuid": "cbcbab5eb48523d4766e6233e62bfafd5fd15f31", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180430.html", "section_title": "Archive News &amp; Video for Monday, 30 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-karyopharm-announces-positive-top/brief-karyopharm-announces-positive-top-line-data-from-phase-2b-storm-study-evaluating-selinexor-in-patients-with-penta-refractory-multiple-myeloma-idUSFWN1S71C4", "country": "US", "domain_rank": 408, "title": "BRIEF-Karyopharm Announces Positive Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.403, "site_type": "news", "published": "2018-05-01T04:30:00.000+03:00", "replies_count": 0, "uuid": "cbcbab5eb48523d4766e6233e62bfafd5fd15f31"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-karyopharm-announces-positive-top/brief-karyopharm-announces-positive-top-line-data-from-phase-2b-storm-study-evaluating-selinexor-in-patients-with-penta-refractory-multiple-myeloma-idUSFWN1S71C4", "ord_in_thread": 0, "title": "BRIEF-Karyopharm Announces Positive Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma", "locations": [], "entities": {"persons": [{"name": "selinexor", "sentiment": "none"}], "locations": [{"name": "boston", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "karyopharm therapeutics inc", "sentiment": "neutral"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30 (Reuters) - Karyopharm Therapeutics Inc:\n* KARYOPHARM ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA\n* KARYOPHARM THERAPEUTICS INC - SELINEXOR CONTINUES TO DEMONSTRATE A PREDICTABLE AND MANAGEABLE TOLERABILITY PROFILE\n* KARYOPHARM THERAPEUTICS INC - COMPANY PLANS TO SUBMIT A NEW DRUG APPLICATION TO FDA IN SECOND HALF OF 2018\n* KARYOPHARM THERAPEUTICS INC - REGARDING STORM STUDYâ€™S PRIMARY OBJECTIVE, ORAL SELINEXOR ACHIEVED A 25.4% OVERALL RESPONSE RATE\n* KARYOPHARM THERAPEUTICS INC - PLANS TO SUBMIT A MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY IN EARLY 2019\n* KARYOPHARM THERAPEUTICS INC - EXPECTING TO COMPLETE ENROLLMENT IN BOSTON STUDY BY END OF 2018, WITH TOP-LINE DATA ANTICIPATED IN 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-01T04:30:00.000+03:00", "crawled": "2018-05-01T19:54:15.018+03:00", "highlightTitle": ""}